# Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

> **NCT05780567** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 1946 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
- **DRUG:** Placebo capsules, Letrozole, Anastrozole, Tamoxifen

## Key facts

- **NCT ID:** NCT05780567
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 1946 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780567, "Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05780567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*